Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

Neurology

Volumn 75, Issue 9, 2010, Pages 831-833

  Lenhard, T ^a   Biller, A ^a   Mueller, W ^a   Metz, I ^b   Schonberger J ^c   Wildemann, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Klinikum Pforzheim GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATININE; LACTIC ACID; METHYLPREDNISOLONE; N ACETYLASPARTIC ACID; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN BIOPSY; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBELLUM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FRONTAL LOBE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LACTATE BLOOD LEVEL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; QUADRIPLEGIA; TEMPORAL LOBE; WHITE MATTER; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77956391379     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f07362     Document Type: Article

References (7)

1. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007;13:79-95.
2. Fox RJ, Kappos L. Is natalizumab overshooting its rebound? Neurology 2008;70:1073-1074.
3. Stüve O, Marra CM, Jerome KR, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-1387.
4. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-582.
5. Michaelis T, Merboldt KD, Bruhn H, et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993;187:219-227.
6. Knysz B, Bolanowski M, Klimczak M, Gladysz A, Zwolin-ska K. Graves' disease as an immune reconstitution syndrome in an HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review. Viral Immunol 2006;19:102-107.
7. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009;361: 1075-1080.